ClinicalTrials.gg
Active, not recruitingNCT05003843Updated Sep 8, 2026

BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

An interventional study of Indigo Aspiration System in Deep Vein Thrombosis and DVT, sponsored by Penumbra Inc.. Active, not recruiting at 42 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Penumbra Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
229
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 246 studies in Venous Thrombosis with a site in United States — 23 open to participants now, 31 under way, 5 of them phase 3. Venous Thrombosis · United States.

Enrollment
74th of 184
229 · median 130
Started
2021
with 9 others
No phase
79 of 246
6 open now
Primary completion
2025-11
later than 3 of 30 live
Registered
207th of 246
by date

Among the 246 studies in Venous Thrombosis with a site in United States, this one is the 74th largest by enrollment of the 184 interventional ones that give a count, is one of 10 that started in 2021, is one of 79 with no phase, reaches primary completion later than 3 of the 30 other live ones, and was the 207th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

23 of the 246 studies in Venous Thrombosis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Venous Thrombosis with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.

03

Conditions studied

  • Deep Vein Thrombosis
  • DVT

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral lower extremity DVT occlusion involving iliac and/or common femoral veins with up to 2 cm extension in the inferior vena cava (IVC) or femoral in combination with iliac veins, including patients with extension of clot into the contralateral common iliac vein Note: Patients with non-iliofemoral DVT in the contralateral limb, who do not require endovascular treatment, may be enrolled
  • Acute thrombotic or thromboembolic occlusion with symptom duration of 14 days or less at presentation
  • Frontline treatment with Indigo Aspiration System in the target venous segment per Investigator decision
  • Patient is ≥18 years of age
  • is obtained per Institutional Review Board requirements

Exclusion criteria

Exclusion Criteria:

  • to systemic or therapeutic doses of anticoagulants
  • Contraindication to iodinated contrast venography that cannot be adequately premedicated
  • Complete infrarenal IVC occlusion
  • In the index leg: prior DVT
  • Prior stent in target venous segment
  • Treatment of index DVT with thrombolytics within 14 days prior to index procedure
  • Pulmonary embolism (PE) defined as either high (systolic blood pressure \< 90 mmHg and/or patient on IV vasoactive medication to support blood pressure), or intermediate high-risk PE, as defined by the European Society Guideline on management of PE. Low risk PE and/or intermediate low risk PE can be enrolled.
  • Known coagulation disorders both acquired (e.g., Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable state
  • Pregnant patients
  • \<1 year due to comorbidities
  • Primary brain, cancer or marrow
  • Current participation in another drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.
  • Other medical, behavioral, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
  • Pre-existing malpositioned stent(s) that obstructs the ostium of the index iliac vein and contacts the vena cava wall as demonstrated by venography prior to the index procedure
  • Congenital anatomic anomalies of the IVC or iliac veins
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Other
    Single Arm

    Use of Indigo Aspiration System in patients with obstruction due to DVT

    Device: Indigo Aspiration System

Interventions

  • DeviceIndigo Aspiration System

    Indigo Aspiration System

06

What researchers measure

Primary outcomes

  1. Composite of Major Adverse Events

    Device related death, major bleeding, new symptomatic pulmonary embolism or re-thrombosis of the target venous segment and serious device related events

    Time frame: 48 Hours Post-Procedure

  2. Change in Marder Score

    Complete or near complete (75% or greater) reduction of venous thrombus from the target venous segment as measured by Marder Score pre- to post-procedure The Marder Score ranges from 0 to 24, with higher scores being worse.

    Time frame: Index Procedure

Secondary outcomes

  1. Composite of Major Adverse Events

    A composite of death, major bleeding, new symptomatic pulmonary embolism or re-thrombus of the target venous segment

    Time frame: 30 Days Post-Procedure

  2. Device Related Adverse Events

    Proportion of participants with device related adverse events

    Time frame: 24 Months

  3. Villalta Scale

    Villalta scores reported at baseline, 30 days, 180 days, 12 months, and 24 months Villalta score ranges from 0 (no post thrombotic syndrome) to 33 (severe post thrombotic syndrome), with higher scores being worse.

    Time frame: 24 Months

07

Study locations

42 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Nov 2025, 49 months.

Of 117 interventional studies with no phase under Venous Thrombosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 56. This study's 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 12, 2021
StartActual
Sep 30, 2021
Primary completionActual
Nov 18, 2025
CompletionEst.
Jan 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05003843
Lead sponsor
Penumbra Inc.
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Sep 30, 2021
Primary completion
Nov 18, 2025
Completion
Jan 2028 (estimated)
Last update
Sep 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion